A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies
Phase of Trial: Phase I
Latest Information Update: 18 Apr 2018
At a glance
- Drugs Atezolizumab (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions
- 08 Mar 2017 Status changed from not yet recruiting to recruiting.
- 23 Feb 2017 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2020.
- 17 Aug 2016 New trial record